Madrigal Pharmaceuticals (MDGL) reported a loss of $7.10 per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of $7.55. In the year-ago quarter, the company reported a loss of $4.69. During the quarter, the company generated total revenues of $14.6 million — entirely from product sales of its recently approved nonalcoholic steatohepatitis (NASH) drug Rezdiffra, which was commercially launched this April. The metric beat the Zacks Consensus Estimate of $3.8 million. Since th ...